-

Amplitude Surgical - Consolidated Annual Sales of €100.2m, up +14.0% at Constant Exchange Rates

  • Consolidated sales of €100.2m, up 14.0% at constant exchange rates
  • Strong 15.8% increase in sales in France, representing 73% of Group sales

VALENCE, France--(BUSINESS WIRE)--Regulatory News:

Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible), a leading French player on the surgical technology market for lower-limb orthopedics, announces its consolidated sales for fiscal year 2022-23.

Olivier Jallabert, Amplitude Surgical’s CEO, commented: "Group sales for the 2022-23 financial year, corresponding solely to the knees and hips business, are up +14.0% at constant exchange rates on the previous year. Sales growth was driven in particular by a +15.8% increase in business in France, which benefited from a favorable sales dynamic".

Consolidated sales for fiscal 2022-2023

Following the announcement on June 29, 2023 of the finalization of the disposal of Novastep's extremities business, sales are presented for the knees and hips business only.

Sales FY 2022-23

30/06/2023

30/06/2022

Change at current
exchange rates

Change at constant
exchange rates

€ thousands - IFRS

Knee and hip activities

100,201

87,559

14.4%

14.0%

Total

100,201

87,559

14.4%

14.0%

Sales Q4 2022-23

30/06/2023

30/06/2022

Change at current
exchange rates

Change at constant
exchange rates

€ thousands - IFRS

Knee and hip activities

24,784

22,994

7.8%

9.0%

Total

24,784

22,994

7.8%

9.0%

Amplitude Surgical sales for FY 2022-23 came to €100.2 million, up 14.4% and 14.0% at constant exchange rates.

Sales in France were up 15.8%, while international distributors were up 11.5%, and the Group's international subsidiaries reported growth of 10.6% at current exchange rates and 8.7% at constant exchange rates.

Amplitude Surgical's direct sales (French market and international subsidiaries), which account for almost 93% of total Group sales, rose by +14.2% at constant exchange rates.

In France, the Group benefited from favorable sales momentum throughout the year. France accounts for around 73% of Group sales.

For international subsidiaries, overall performance was up, but the level of activity varied according to geographic zone: business was up in Brazil, Benelux and South Africa, while Australia and Germany saw a decline in sales.

Next press release:

Annual results 2022-23: Wednesday, October 18, 2023, after market close.

About Amplitude Surgical

Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player on the global surgical technology market for lower-limb orthopedics. Amplitude Surgical develops and markets high-end products for orthopedic surgery covering the main disorders affecting the hip and knee. Amplitude Surgical develops, in close collaboration with surgeons, numerous high value-added innovations in order to best meet the needs of patients, surgeons and healthcare facilities. A leading player in France, Amplitude Surgical is developing abroad through its subsidiaries and a network of exclusive distributors and agents distributing its products in more than 30 countries. As of June 30, 2023, Amplitude Surgical employed 424 people and generated sales of nearly 100.2 million euros.

Contacts

Amplitude Surgical
CFO
Dimitri Borchtch
finances@amplitude-surgical.com
+33 (0)4 75 41 87 41

NewCap
Investor Relations
Thomas Grojean
amplitude@newcap.eu
+33 (0)1 44 71 94 94

NewCap
Media Relations
Nicolas Merigeau
amplitude@newcap.eu
+33 (0)1 44 71 94 98

Amplitude Surgical

BOURSE:AMPLI

Release Versions

Contacts

Amplitude Surgical
CFO
Dimitri Borchtch
finances@amplitude-surgical.com
+33 (0)4 75 41 87 41

NewCap
Investor Relations
Thomas Grojean
amplitude@newcap.eu
+33 (0)1 44 71 94 94

NewCap
Media Relations
Nicolas Merigeau
amplitude@newcap.eu
+33 (0)1 44 71 94 98

More News From Amplitude Surgical

Amplitude Surgical SA: Results of the Simplified Tender Offer

VALENCE, France--(BUSINESS WIRE)--Regulatory News: Amplitude Surgical (ISIN: FR0012789667, Ticker: AMPLI, eligible for PEA-PME), the French leader in surgical technologies for lower limb orthopedics. On 10 October 2025, the French Autorité des Marchés Financiers (AMF) announced the results of the simplified tender offer initiated by Zydus MedTech (France) SAS on Amplitude Surgical SA shares, following the closing of the offer on 9 October 2025. At the end of the offer, Zydus MedTech (France) SA...

Zydus Announces Completion of the Acquisition of an 85.6% Stake in Amplitude Surgical and Upcoming Filing of a Simplified Tender Offer

AHMEDABAD, India & VALENCE, France--(BUSINESS WIRE)--Regulatory News: Zydus Lifesciences Limited1 (“Zydus”), on March 11, 2025, entered into agreements with PAI and two minority shareholders of Amplitude Surgical (Paris:AMPLI) to acquire blocks of shares representing in aggregate 85.6% of Amplitude Surgical’s share capital and voting rights2 at a price of €6.25 per share and a total consideration of €256.8mn (the “Block Acquisition”). As all conditions precedent to the completion have now been...

Amplitude Surgical – Suspension of Listing

VALENCE, France--(BUSINESS WIRE)--Regulatory News: Amplitude Surgical company has requested Euronext to suspend the listing of its shares (ISIN: FR0012789667, Ticker: AMPLI, eligible PEA-PME) on Euronext market with effect as from the publication of this press release and pending publication of a further press release. About Amplitude Surgical Founded in 1997 in Valence, Amplitude Surgical is a leading French player in the global market for surgical technologies for lower limb orthopedics. Ampl...
Back to Newsroom